ArticleMedical science monitor : international medical journal of experimental and clinical research2025
R1 Resection in Gastric Cancer: Marker of Tumor Biology Rather Than Surgical Failure.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Microscopically positive margins (R1) after gastrectomy are uncommon but are associated with poor outcomes. Whether R1 reflects inadequate surgery or aggressive tumor biology remains unclear. MATERIAL AND METHODS We retrospectively analyzed 28 patients who underwent R1 resection for gastric adenocarcinoma between 2010 and 2023. Clinicopathologic features, recurrence patterns, and overall survival (OS) were evaluated. Prognostic factors were identified using univariate and multivariate Cox regression. RESULTS After a median follow-up of 82 months, the 5-year OS was 21.4%. Recurrence occurred in 50% of patients, all of whom subsequently died. On univariate analysis, HER2 negativity (HR 0.60, 95% CI 0.41-0.87, P=0.007), high Ki-67 index (HR 1.03, 95% CI 1.01-1.05, P=0.004), poor differentiation (HR 2.40, 95% CI 1.26-4.55, P=0.008), advanced pathological stage (HR 15.87, 95% CI 3.79-66.40, P<0.001), high lymph node ratio (HR 245.63, 95% CI 20.60-2929.13, P<0.001), and signet ring histology (HR 5.29, 95% CI 1.94-14.43, P=0.001) were associated with inferior OS. Multivariate analysis confirmed signet ring histology (HR 6.00, 95% CI 1.32-27.22, P=0.020) and advanced pathological stage (HR 13.28, 95% CI 2.76-63.89, P=0.001) as independent adverse prognostic factors, whereas lymph node ratio demonstrated borderline significance (HR 35.77, 95% CI 0.98-1308.06, P=0.051). CONCLUSIONS Survival after R1 resection is determined mainly by tumor biology - particularly signet ring features and advanced stage - rather than surgical technique. These findings call for risk-adapted adjuvant strategies and refined prognostic models in this high-risk subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.